Antiproliferative activity of phenylbutyrate ester of haloperidol metabolite II [(±)-MRJF4] in prostate cancer cells

European Journal of Medicinal Chemistry

Volumn 46, Issue 1, 2011, Pages 433-438

  Marrazzo, Agostino ^a   Fiorito, Jole ^a   Zappal, Laura ^a   Prezzavento, Orazio ^a   Ronsisvalle, Simone ^a   Pasquinucci, Lorella ^a   Scoto, Giovanna M ^a   Bernardini, Renato ^a   Ronsisvalle, Giuseppe ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Histone deacetylase; Inhibitors; LNCaP; PC3; Sigma receptors

Indexed keywords

4 [4 (4 CHLOROPHENYL) 4 HYDROXYPIPERIDIN 1 YL] 1 (4 FLUOROPHENYL)BUTYL 4 PHENYLBUTANOATE; 4 PHENYLBUTYRIC ACID; AC 927; ANTINEOPLASTIC AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; HALOPERIDOL; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MRJF 4; OPIATE ANTAGONIST; PENTAZOCINE; SIGMA OPIATE RECEPTOR; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; PROSTATE CANCER;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; GUINEA PIGS; HALOPERIDOL; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MALE; PHENYLBUTYRATES; PROSTATIC NEOPLASMS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, SIGMA;

EID: 78650514390     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2010.10.012     Document Type: Article

References (41)

1. L.C. Li Front. Biosci. 12 2007 3377 3397
2. A.I. So, A. Hurtado-Coll, and M.E. Gleave World J. Urol. 21 2003 325 337
3. K. Iguchi, M. Ito, S. Usui, A. Mizokami, M. Namiki, and K. Hirano J. Androl. 29 2008 207 212
4. F. Stavridi, E.M. Karapanagiotou, and K.N. Syrigos Cancer Treat. Rev. 36 2010 122 130
5. B.A. Hadaschik, R.D. Sowery, and M.E. Gleave Curr. Opin. Urol. 17 2007 182 187
6. K.V. Balakin, Y.A. Ivanenkov, A.S. Kiselyov, and S.E. Tkachenko Anticancer Agents Med. Chem. 7 2007 576 592
7. H. Hess-Stumpp Eur. J. Cell Bio. 84 2005 109 121
8. S. Mei, A.D. Ho, and U. Mahlknecht Int. J. Oncol. 25 2004 1509 1519
9. R. Somech, S. Izraeli, and A.J. Simon Cancer Treat. Rev. 30 2004 461 472
10. P. Jones, S. Altamura, R. De Francesco, O.G. Paz, O. Kinzel, G. Mesiti, E. Monteagudo, G. Pescatore, M. Rowley, M. Verdirame, and C. Steinkühler J. Med. Chem. 51 2008 2350 2353
11. L.C. Boffa, G. Vidali, R.S. Mann, and V.G. Allfrey J. Biol. Chem. 253 1978 3364 3366
12. M.W. Sung, and S. Waxman Anticancer Res. 27 2007 995 1001
13. L.H. Camacho, J. Olson, W.P. Tong, C.W. Young, D.R. Spriggs, and M.G. Malkin Invest. New Drugs 25 2007 131 138
14. R.R. Matsumoto, W.D. Bowen, and T.P. Su Sigma Receptors Chemistry, Cell Biology and Clinical Implications 2007 Springer Science+Business Media, LLC New York
15. M. Hanner, F.F. Moebius, A. Flandorfer, G. H-Knaus, J. Striessnig, E. Kempner, and H. Glossmann Proc. Natl. Acad. Sci. USA 93 1996 8072 8077
16. S.B. Hellewell, A. Bruce, G. Feinstein, J. Orringer, W. Williams, and W.D. Bowen Eur. J. Pharmacol. 268 1994 9 18
17. H. Kashiwagi, J.E. McDunn, P.O. Simon Jr., P.S. Goedegebuure, J. Xu, L. Jones, K. Chang, F. Johnston, K. Trinkaus, R.S. Hotchkiss, R.H. Mach, and W.G. Hawkins Mol. Cancer 6 2007 48 60
18. K.T. Wheeler, L.M. Wang, C.A. Wallen, S.R. Childers, J.M. Cline, P.C. Keng, and R.H. Mach Br. J. Cancer 82 2000 1223 1232
19. C.S. John, B.J. Vilner, B.C. Geyer, T. Moody, and W.D. Bowen Cancer Res. 59 1999 4578 4583
20. C.S. John, M.E. Gulden, J. Li, W.D. Bowen, J.G. McAfee, and M.L. Thakur Nucl. Med. Biol. 25 1998 189 194
21. R. Banerjee, P. Tyagi, S. Li, and L. Huang Int. J. Cancer 112 2004 693 700
22. S.D. Li, Y.C. Chen, M.J. Hackett, and L. Huang Mol. Ther. 16 2008 163 169
23. S.D. Li, and L. Huang Mol. Pharm. 3 2006 579 588
24. P.J. Brent, G. Pang, G. Little, P.J. Dosen, and D.F. Van Helden Biochem. Biophys. Res. Commun. 219 1996 219 226
25. B.J. Vilner, W.D. Bowen, and J. Pharmacol Exp. Ther. 292 2000 900 911
26. W.D. Bowen, E.L. Moses, P.J. Tolentino, and J.M. Walker Eur. J. Pharmacol. 177 1990 111 118
27. J.C. Jaen, B.W. Caprathe, T.A. Pugaley, and L.D. Wise J. Med. Chem. 36 1993 3929 3936
28. A. Azzariti, N.A. Colabufo, F. Berardi, L. Porcelli, M. Niso, G.M. Simone, R. Perrone, and A. Paradiso Mol. Cancer Ther. 5 2006 1807 1816
29. M. Tucci, C. Quartaro, F. Dammacco, and F. Silvestris Curr. Top. Med. Chem. 9 2009 218 224
30. S. Hauswald, J. Dunque-Anfoso, M.M. Wagner, F.M. Schertl, M. Lubbert, C. Peschel, K. Ulrich, and T. Licht Clin. Cancer Res. 15 2009 3705 3715
31. N.A. Colabufo, F. Berardi, M. Contino, M. Niso, C. Abate, R. Perrone, and V. Tortorella Naunyn Schmiedebergs Arch. Pharmacol. 370 2004 106 113
32. B.A. Spruce, L.A. Campbell, N. McTavish, M.A. Cooper, M.V.L. Appleyard, M. O'Neil, J. Howie, J. Sanson, S. Watt, K. Murray, D. McLean, N.R. Leslie, S.T. Safrany, M.J. Ferguson, J.A. Peters, A.R. Prescott, G. Box, A. Hayes, B. Nutley, F. Raynaud, C.I. Downes, J.J. Lambert, A.M. Thomson, and S. Eccles Cancer Res. 64 2004 4875 4886
33. W.D. Bowen Pharm. Acta Helv. 74 2000 211 218
34. R.R. Matsumoto, J. Shaikh, L.L. Wilson, S. Vedam, and A. Coop Eur. Neuropsychopharmacol. 18 2008 871 881
35. R. Matsumoto, W.D. Bowen, M.A. Tom, V.N. Vo, D.D. Truong, and B.R. De Costa Eur. J. Pharmacol. 280 1995 301 310
36. R.H. Mach, C.R. Smith, and S.R. Childers Life Sci. 57 1995 L57 L62
37. T. Mennini, P. Bernasconi, and M.G. Fiori Invest. Radiol. 28 1993 821 827
38. J. Carmichael, W.G. DeGraff, A.F. Gazdar, J.D. Minna, and J.B. Mitchell Cancer Res. 47 1987 943 946
39. G. Cantarella, G. Di Benedetto, S. Pezzino, N. Risuglia, and R. Bernardini J. Neurochem. 105 2008 1915 1923
40. T. Liu, G. Kapustin, and F.A. Etzkorn J. Med. Chem. 50 2007 2003 2006
41. A.J. de Ruijter, S. Kemp, G. Kramer, R.J. Meinsma, J.O. Kaufmann, H.N. Caron, and A.B. van Kuilenburg Biochem. Pharmacol. 68 2004 1279 1288